Pharming Group (NASDAQ:PHAR - Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.01 per share for the quarter.
Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its earnings results on Thursday, March 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.05 by ($0.08). Pharming Group had a negative net margin of 4.13% and a negative return on equity of 4.53%. The firm had revenue of $81.20 million during the quarter, compared to analyst estimates of $71.83 million. On average, analysts expect Pharming Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Pharming Group Stock Up 7.0 %
Shares of NASDAQ PHAR traded up $0.68 during midday trading on Wednesday, reaching $10.45. The company's stock had a trading volume of 1,078 shares, compared to its average volume of 2,551. The stock has a 50 day simple moving average of $10.76 and a 200-day simple moving average of $11.38. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $701.30 million, a price-to-earnings ratio of -74.64 and a beta of 0.16. Pharming Group has a fifty-two week low of $9.27 and a fifty-two week high of $16.71.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a "buy" rating and issued a $37.00 price target on shares of Pharming Group in a research note on Thursday, March 14th.
Get Our Latest Analysis on Pharming Group
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
